Bibliography
- Levi M , HobbsFD, JacobsonAKet al.: Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives.Semin. Thromb. Hemost., 35, 527–547 (2009).
- Connolly SJ , EzekowitzMD, YusufSet al.: Dabigatran versus warfarin in patients with atrial fibrillation.N. Engl. J. Med., 361, 1139–1151 (2009).
- Saravanen P , DavidsonNC, SchmidtEB, CalderPC: Cardiovascular effects of marine omega-3 fatty acids.Lancet, 376, 540–550 (2010).
- Rauch B , SchieleR, SchneiderSet al.: OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.Circulation, 122, 2152–2159 (2010).
- McMurray JJ : Clinical practice. Systolic heart failure.N. Engl. J. Med., 362, 228–238 (2010).
- Pitt B , ZannadF, RemmeWet al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.N. Engl. J. Med., 341, 709–717 (1999).
- Pitt B , RemmeW, ZannadFet al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.N. Engl. J. Med., 348, 1309–1321 (2003).
- Zannad F , McMurrayJJ, KrumHet al.: Eplerenone in patients with systolic heart failure and mild symptoms.N. Engl. J. Med., 364, 11–21 (2011).
- Cleland JG , DaubertJC, ErdmannEet al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure.N. Engl. J. Med., 352, 1539–1549 (2005).
- Bristow MR , SaxonLA, BoehmerJet al.: Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.N. Engl. J. Med., 350, 2140–2150 (2004).
- Moss AJ , HallWJ, CannonDSet al.: Cardiac-resynchronization therapy for the prevention of heart-failure events.N. Engl. J. Med., 361, 1329–1338 (2010).
- Tang AS , WellsGA, TalajicMet al.: Cardiac-resynchronization therapy for mild-to-moderate heart failure.N. Engl. J. Med., 363, 2385–2395 (2010).
- Maric B , KaanA, IgnaszewskiA, LearSA: A systemic review of telemonitoring technologies in heart failure.Eur. J. Heart Fail., 11, 506–517 (2009).
- Chaudhry SI , MatteraJA, CurtisJPet al.: Telemonitoring in heart failure patients.N. Engl. J. Med., 363, 2301–2309 (2010).
- Koehler F , WinklerS, SchieberMet al.: Telemedical interventional monitoring in heart failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design.Eur. J. Heart Fail., 12, 1354–1362 (2010).
- Braun M , GliechV, BoscheriAet al.: Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results in three different device occluder systems.Eur. Heart J., 25, 424–430 (2004).
- Wiviott SD , BraunwaldE, McGabeCHet al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes.N. Engl. J. Med., 357, 2001–2015 (2007).
- Cannon CP , HarringtonRA, JamesSet al.: Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study.Lancet, 375, 283–293 (2010).
- Tepel M et al. , van der Giet M, Schwarzfeld C : Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med., 343, 180–184 (2000).
Website
- Scientific sessions 2010 archive http://scientificsessions.americanheart.org/2010archive.shtml